Santa Clara, California, and Bengaluru, India, January 13, 2026. Applied Cells Inc. announced today a strategic collaboration framework with Immuneel Therapeutics Private Limited to jointly evaluate the application of Applied Cells’ MARS® Atlas platform and GoFast™ CAR-T workflow for future CAR-T therapy development and manufacturing.
Under this collaboration, the two companies will work together to integrate the MARS® Atlas platform and GoFast™ workflow into selected Immuneel CAR-T programs. The shared objective is to significantly improve the affordability and accessibility of CAR-T therapies, beginning in India, with the potential for broader global adoption.
A key focus of the collaboration is achieving manufacturing costs that enable truly affordable CAR-T therapy for the majority of eligible patients in India, while maintaining therapeutic efficacy comparable to currently approved CAR-T treatments. ‘We are thrilled to partner with Immuneel, a pioneer in bringing cutting‑edge cell therapies to India,’ said Yuchen Zhou, CEO of Applied Cells. ‘The combination of MARS® Atlas and the GoFast™ workflow with Immuneel’s clinical and regulatory capabilities has the potential to transform the CAR‑T landscape by making these life‑saving treatments accessible to millions who currently cannot afford them.’
‘At Immuneel, our mission is to make advanced cell therapies accessible and affordable for patients who need them the most,’ said Amit Mookim, CEO of Immuneel Therapeutics. ‘This collaboration represents an important step in evaluating innovative technologies that could strengthen our manufacturing capabilities and support development of scalable, cost‑effective CAR‑T solutions. We look forward to jointly exploring how platforms like MARS® Atlas and the GoFast™ workflow could contribute to expanding access to high‑quality cell therapies in India and beyond.’
Both companies have commenced collaborative activities and will share updates as the programs progress. You can read the full press release announcement here.
About Immuneel Therapeutics
Immuneel Therapeutics is a clinical-stage biotechnology company developing affordable, best-in-class cell and gene therapies, with a focus on CAR-T therapies for cancer patients in India and emerging markets. Immuneel is committed to building a sustainable, end-to-end cell therapy ecosystem that delivers world-class treatments at accessible price points.
Media Contacts Applied Cells : info@appliedcells.com; Immuneel : reachus@immuneel.com
Kat Ginda-Mäkelä
